Summary & Overview
HCPCS J1740: Ibandronate Sodium Injection, 1 mg
HCPCS Level II code J1740 designates the injectable formulation of ibandronate sodium at 1 mg per unit. Ibandronate is a bisphosphonate used in conditions affecting bone metabolism, and the HCPCS code is applied when the drug is supplied for injectable administration in outpatient settings. Nationally, accurate coding for drug units affects claims processing, coverage determination, and aggregate spending on specialty injectable medications.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for ibandronate injections, typical sites of service where J1740 is billed, and the payer landscape relevant to coverage and billing practice. The publication summarizes available benchmarks, common billing modifiers (listed elsewhere), and policy considerations that influence reimbursement and claim adjudication. It also outlines operational considerations for facilities and clinicians billing for injectable bisphosphonate therapy.
Data not available in the input are noted where applicable; the document focuses on national implications rather than state-specific rules.
Billing Code Overview
HCPCS Level II code J1740 represents injection, ibandronate sodium, 1 mg. This code is used to bill for the drug formulation delivered as an injectable therapy.
-
Service type: Injectable medication administration for intravenous or intramuscular delivery of ibandronate sodium.
-
Typical site of service: Hospital outpatient departments, physician offices, infusion centers, and other outpatient settings where injectable medications are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman or an adult with glucocorticoid-induced osteoporosis who presents for treatment to reduce risk of vertebral and nonvertebral fractures. The patient has had baseline evaluation including bone mineral density (DEXA) testing showing osteoporosis (T-score ≤ -2.5) or a history of fragility fracture and has been prescribed intravenous or injectable ibandronate sodium. The service J1740 is administered in an outpatient infusion or injection clinic, physician office, or ambulatory care center. Clinical workflow: the patient checks in, vitals and recent laboratory review (serum calcium, renal function) are confirmed, informed consent for the infusion/injection is documented, medication is prepared and verified by the clinician/pharmacist, the clinician or qualified nursing staff administers the injection per protocol, post‑administration observation for adverse effects is performed (typically 15–30 minutes), and documentation includes dose, lot number, route, site of administration, any immediate reaction, and any applicable modifier (e.g., if discarded or wasted portion).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard billing | Use when no special circumstances apply and a single service is billed normally. |